 <h1>Vosevi Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>sofosbuvir / velpatasvir / voxilaprevir</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about sofosbuvir / velpatasvir / voxilaprevir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Vosevi.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to sofosbuvir/velpatasvir/voxilaprevir: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with sofosbuvir / velpatasvir / voxilaprevir. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, sofosbuvir / velpatasvir / voxilaprevir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking sofosbuvir / velpatasvir / voxilaprevir:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Chest pain or discomfort</li>
<li>dark-colored urine</li>
<li>headache</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>light-colored stools</li>
<li>skin rash, sometimes with blisters or hive-like swelling</li>
<li>slow or irregular heartbeat</li>
<li>stomach pain, continuing</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of sofosbuvir / velpatasvir / voxilaprevir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>lack or loss of strength</li>
<li>nausea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Discouragement</li>
<li>feeling sad or empty</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>tiredness</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sofosbuvir / velpatasvir / voxilaprevir: oral tablet</i></p><h3>General</h3><p>The most common side effects reported with this drug were headache, fatigue, diarrhea, and nausea.  This drug was permanently discontinued due to side effects in up to 0.2% of patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 27%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 24%)</p>
<p><b>Common</b> (1% to 10%): Asthenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 20%), nausea (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Elevated lipase, abdominal pain, vomiting<sup>[Ref]</sup></p><p>Isolated, asymptomatic lipase elevations (greater than 3 times the upper limit of normal [3 x ULN]) were reported in 2% of patients.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Due to inhibition of OATP1B1 and OATP1B3 by voxilaprevir, increased total bilirubin (up to 1.5 x ULN) occurred with this drug.  No jaundice was observed and total bilirubin levels decreased after completion of therapy.</p>
<p></p>
<p>Cases of hepatic decompensation/failure (including fatal outcomes) have been reported during postmarketing experience in patients treated with hepatitis C virus nonstructural protein 3/4A (NS3/4A) protease inhibitor-containing regimens (including this drug).  Reported cases occurred in patients with baseline cirrhosis with and without moderate or severe liver dysfunction (Child-Pugh B or C).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased total bilirubin (up to 13%)</p>
<p><b>Postmarketing reports</b>: Hepatic decompensation, hepatic failure<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Uncommon</b> (0.1% to 1%): Depressed mood<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Sofosbuvir-containing regimens:</p>
<p>-Frequency not reported: Severe bradycardia, heart block</p>
<p>-Postmarketing reports: Serious symptomatic bradycardia (including fatal cardiac arrest, cases requiring pacemaker intervention)<sup>[Ref]</sup></p><p>Severe bradycardia and heart block have been reported when sofosbuvir-containing regimens were used in combination with amiodarone and/or other agents that lower heart rate.</p>
<p></p>
<p>Serious symptomatic bradycardia has been reported in patients taking amiodarone who started therapy with a regimen containing sofosbuvir.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Frequency not reported</b>: Stevens-Johnson syndrome</p>
<p></p>
<p>Sofosbuvir-containing regimens:</p>
<p>-Postmarketing reports: Skin rashes (sometimes with blisters or angioedema-like swelling), angioedema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Isolated, asymptomatic creatine kinase elevations (at least 10 x ULN) were reported in up to 1% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Back pain, myalgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Elevated creatine kinase, muscle spasm<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased appetite</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Vosevi (sofosbuvir / velpatasvir / voxilaprevir)." Gilead Sciences, Foster City, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What types of hepatitis C (HCV) does Vosevi treat?</li>
<li>What are the new drugs for the treatment of hepatitis C?</li>
<li>What is the difference between Vosevi and Epclusa?</li>
<li>Does Vosevi cure hepatitis C?</li>
<li>How much does Vosevi cost?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Vosevi (sofosbuvir / velpatasvir / voxilaprevir)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: antiviral combinations</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Vosevi &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hepatitis C</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sofosbuvir / velpatasvir / voxilaprevir: oral tablet</i></p><h3>General</h3><p>The most common side effects reported with this drug were headache, fatigue, diarrhea, and nausea.  This drug was permanently discontinued due to side effects in up to 0.2% of patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 27%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 24%)</p><p><b>Common</b> (1% to 10%): Asthenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 20%), nausea (up to 14%)</p><p><b>Common</b> (1% to 10%): Elevated lipase, abdominal pain, vomiting<sup>[Ref]</sup></p><p>Isolated, asymptomatic lipase elevations (greater than 3 times the upper limit of normal [3 x ULN]) were reported in 2% of patients.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Due to inhibition of OATP1B1 and OATP1B3 by voxilaprevir, increased total bilirubin (up to 1.5 x ULN) occurred with this drug.  No jaundice was observed and total bilirubin levels decreased after completion of therapy.</p><p></p><p>Cases of hepatic decompensation/failure (including fatal outcomes) have been reported during postmarketing experience in patients treated with hepatitis C virus nonstructural protein 3/4A (NS3/4A) protease inhibitor-containing regimens (including this drug).  Reported cases occurred in patients with baseline cirrhosis with and without moderate or severe liver dysfunction (Child-Pugh B or C).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased total bilirubin (up to 13%)</p><p><b>Postmarketing reports</b>: Hepatic decompensation, hepatic failure<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Uncommon</b> (0.1% to 1%): Depressed mood<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Sofosbuvir-containing regimens:</p><p>-Frequency not reported: Severe bradycardia, heart block</p><p>-Postmarketing reports: Serious symptomatic bradycardia (including fatal cardiac arrest, cases requiring pacemaker intervention)<sup>[Ref]</sup></p><p>Severe bradycardia and heart block have been reported when sofosbuvir-containing regimens were used in combination with amiodarone and/or other agents that lower heart rate.</p><p></p><p>Serious symptomatic bradycardia has been reported in patients taking amiodarone who started therapy with a regimen containing sofosbuvir.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Frequency not reported</b>: Stevens-Johnson syndrome</p><p></p><p>Sofosbuvir-containing regimens:</p><p>-Postmarketing reports: Skin rashes (sometimes with blisters or angioedema-like swelling), angioedema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Isolated, asymptomatic creatine kinase elevations (at least 10 x ULN) were reported in up to 1% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Back pain, myalgia</p><p><b>Uncommon</b> (0.1% to 1%): Elevated creatine kinase, muscle spasm<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased appetite</p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Vosevi (sofosbuvir / velpatasvir / voxilaprevir)." Gilead Sciences, Foster City, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What types of hepatitis C (HCV) does Vosevi treat?</li>
<li>What are the new drugs for the treatment of hepatitis C?</li>
<li>What is the difference between Vosevi and Epclusa?</li>
<li>Does Vosevi cure hepatitis C?</li>
<li>How much does Vosevi cost?</li>
</ul><h2>More about Vosevi (sofosbuvir / velpatasvir / voxilaprevir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: antiviral combinations</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Vosevi &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hepatitis C</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>